65,437 trials
Rheumatoid Arthritis
Primary: Part A: Average Difference Between Baseline and Post Dose Evoked (by Treadmill Walking) Lower-Extremity Pain Intensity Scores (AELEPID) Over the 6 Hours After Dosing…
Peripheral Neuropathy · Neuropathic Pain
Primary: Change From Baseline in Mean Numeric Pain Rating Scale (NPRS) Score — 1.02; 1.74; 1.51 units on a scale
Recurrent Clostridium Difficile Infection
Primary: Incidence of Serious Adverse Events Through 56 Days After the Last Treatment With RBX2660 — 10 number of reported SAEs through 56 days
Prediabetic State · Glucose Intolerance
Primary: Change From Baseline in Weight Parameter — -.58; -.18 kilograms
Erythema Migrans
Primary: Detection of Borrelia Burgdorferi Sensu Lato by Microscopy in Dark Field (Positive vs. Negative) — 102; 59 culture-positive skin samples
Myopia · Astigmatism · Hyperopia
Primary: Percentage of Subjects With Visibly Clean Lenses — 42.0; 57.1; 29.0; 42.9 percentage of subjects
Urinary Incontinence, Stress · Intrinsic Sphincter Deficiency
Primary: Percentage of Subjects With a ≥50% Reduction in Pads Per Day Use — 87.2; 97.6 percentage of participants
Exclusive Breastfeeding · Co-production of Health in Communities
Primary: Number of Participants With Changes in Knowledge — 12; 2; 11; 3 participants
Breast Cancer
Primary: Percentage of Participants With Second-Line Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) — 88.7…
Cardiovascular Diseases
Primary: Time to Event Analysis: Number of Patients Who Experienced the First Cardiovascular Hospitalization Within 2 Years Post-implant — 43; 40 number of participants — p=0.72
Myopia · Hyperopia
Primary: Dryness (During Day and Dryness at Night) — 69; 53 units on a scale
Breast Cancer
Primary: Number of Patients With Decreased Gene Expression of CYP19 in Breast Cancer by Adding COX-2 Inhibitor to Exemestane — 0; 0 patients
Seasonal Allergic Rhinitis
Primary: Primary Efficacy — -3.83; -2.77 units on a scale
Focus of Study: Neural Correlates of Oxytocin Administration
Primary: Functional Magnetic Resonance Imaging (fMRI) Data: Change in BOLD Activity Between Placebo and Oxytocin Treatment. — 0.7944; 0.5790; 0.6119; 0.6688 BOLD signal change…
Allergic Rhinitis
Primary: Safety — 43; 39 adverse events